Atlanta, GA | June 2018

Geom Therapeutics Data Presented from Antibiotic 

Drug Development Programs at ASM Microbe

Twelve posters and two oral presentations summarize nonclinical studies of Geom’s novel cephalosporin GT-1 and novel beta-lactamase inhibitor GT-055 -

San Francisco, CA, June 4, 2018 – Geom Therapeutics, Inc., a privately held biopharmaceutical company focused on the development of novel antibiotics for multidrug-resistant (MDR) gram-negative infections, today announced upcoming data presentations at the American Society of Microbiologists (ASM) Microbe 2018 Annual Meeting in Atlanta, GA. Twelve posters and two oral presentations demonstrating the nonclinical results of GT-1, a cephalosporin with a novel uptake mechanism and GT-055, a novel beta-lactamase inhibitor in combination with GT-1, have been accepted for presentation.

 

Dirk Thye, M.D., Executive Chairman of Geom Therapeutics, Inc., said, “We are very excited to introduce our two novel compounds to the infectious diseases scientific community.  GT-1 and GT-055 are intended for the treatment of resistant gram-negative infections, including infections caused by species of Acinetobacter and Pseudomonas, which are among the most critical bacterial threats to human health.  Geom’s presentations at the ASM Microbe 2018 meeting summarize key research and development results and provide the foundation for GT-1 to enter human clinical trials in the second half of 2018.”

Oral Presentation Session 012 - New Agents Discovery Summary Session: Early New Antimicrobial Agents

GT-1: A Novel Siderophore Cephalosporin For MDR Gram-negative Pathogens, As Monotherapy, And In Combination With GT-055, A Novel β-Lactamase Inhibitor;

 

D. Thye

Oral Presentation Session 147 - Trouble-shooting Preclinical Antibacterial Development: A Consensus PK/PD Approach

Pharmacokinetic-Pharmacodynamic (PK-PD) Targets Associated with GT-1 Efficacy against Acinetobacter Baumannii Using the Murine-Thigh Infection Model;

 

J. Bader, E. Lakota, M. Zhao, A. Lepak, B. VanScoy, D. Biek, Y. Cho, S. Bhavnani, P. Ambrose, D. Andes

Poster Presentation Session 233 - AAR04 - Antimicrobial PK/PD & General Pharmacology: in vivo Studies

Number: 552

In Vitro ADME and In Vivo Pharmacokinetic Profiles of GT-1, A Novel Siderophore Cephalosporin, in the Mouse, Rat, and Dog;

 

Y. Cho, H. Kwon, B. Hannah

Number: 554

Pharmacokinetic-Pharmacodynamic (PK-PD) Targets for GT-1 Efficacy Using A Murine-Lung Infection Model;

 

E. Lakota, A. Lepak, M. Zhao, J. Bader, D. Taylor, D. Biek, Y. Cho, S. Bhavnani, P. Ambrose, D. Andes

Number: 556

Pharmacokinetic-Pharmacodynamic (PK-PD) Targets Associated with GT-1 Efficacy against Acinetobacter Baumannii Using the Murine-Thigh Infection Model;

 

J. Bader, E. Lakota, M. Zhao, A. Lepak, B. VanScoy, D. Biek, Y. Cho, S. Bhavnani, P. Ambrose, D. Andes

Poster Presentation Ses­sion 412

AAR08 - New Antimicrobial Agents and New Research Technologies: New Cephalosporins, Penems, and Carbapenems

Number: 571

Antimicrobial Activity of the Novel Siderophore Cephalosporin GT-1 Tested Alone and Combined with the β-Lactamase Inhibitor GT-055 against Molecularly Characterized Enterobacteriaceae Clin. Isolates;

 

H. Sader, L. Duncan, J. Thompson, Y. Cho, D. Biek, R. Flamm

Number: 572

Nonclinical Safety and Toxicological Profile of GT-1, A Novel Siderophore Cephalosporin;

 

S. Azri-Meehan, B. Hannah

Number: 573

GT-1, A Novel Siderophore Cephalosporin, with Potent Activity against Select Biothreat Pathogens Either Alone Or in Combination with A Beta-Lactamase Inhibitor (GT-055);

 

S. Zumbrun, S. Halasohoris, M. Lemmon, P. Desai, L. Miller, S. Int Veldt, Z. Huang, B. Hannah, D. Biek,

R. G. Panchal

Number: 574

Activity of Novel Siderophore Cephalosporin GT-1 and ß-Lactamase Inhibitor GT-055 against Resistant-K. pneumoniae in Time-Kill and Murine Thigh Infection Studies;

 

S-h. Oh, J. Kwak, J. Lee, H. Han, K. Oh, Y. Cho

Number: 575

In Vitro Activity of GT-1 and GT-1/GT-055 against Recent Gram-Negative Clinical Isolates;

 

M. Hackel, D. Biek, Y. Cho, D. Sahm

Number: 576

In Vitro Activity of Novel Siderophore-Cephalosporin, GT-1, and β-Lactamase Inhibitor, GT-055, against KPC- Or OXA-Type Carbapenemase- and ESBL-Producing E. coli, K. pneumonia Clinical Isolates from A Characterized MDR Panel;

 

P. Nguyen, N. Pinto, N. Vu, Y. Cho, J-H. Byun, R. D’Souza, D. Yong, K. Lee 

Number: 577

Antimicrobial Activity of GT-1, A Novel Siderophore Cephalosporin, Tested against Multidrug-Resistant Pseudomonas Aeruginosa And Acinetobacter Spp. Isolates;

 

L. Duncan, P. Rhomberg, D. Biek, Y. Cho, R. Flamm, H. Sader  

Number: 578

Serum and Iron Effects on the In Vitro Activity of Siderophore Cephalosporin GT-1;  

 

S-h. Oh, J. Kwak, J. Lee, H. Han, D. Biek, K. Oh, Y. Cho

Number: 579

Efficacy of the Siderophore Cephalosporin GT-1 against P. Aeruginosa in A Neutropenic Mouse Thigh Model of Infection;

 

K. Oh, D. Kang, D. Biek, Y. Cho

Site map:

Contact Us